| dbo:abstract |
Sitaxentan (Handelsname: Thelin®, Hersteller: , eine Tochterfirma des Pfizer-Konzerns) ist ein Endothelin-Rezeptorantagonist und war als Alternative zu Ambrisentan und Bosentan als so genanntes Orphan-Arzneimittel zur Behandlung des seltenen Lungenbluthochdrucks (Pulmonale Hypertonie, NYHA-Stadium III) zugelassen. (de) Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity. (en) |
| dbo:bioavailability |
70.000000 (xsd:float) |
| dbo:casNumber |
184036-34-8 210421-64-0 (sodium salt) |
| dbo:chEMBL |
282724 |
| dbo:drugbank |
DB06268 |
| dbo:fdaUniiCode |
J9QH779MEM |
| dbo:kegg |
D07171 |
| dbo:pubchem |
216235 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Sitaxentan.svg?width=300 |
| dbo:wikiPageExternalLink |
http://la-press.com/article.php%3Farticle_id=1420 https://archive.today/20030804040032/http:/www.chestjournal.org/cgi/content/abstract/121/6/1860 https://www.drugs.com/nda/thelin_050714.html http://www.americanheart.org/presenter.jhtml%3Fidentifier=4752 |
| dbo:wikiPageID |
2322686 (xsd:integer) |
| dbo:wikiPageLength |
7953 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1073189152 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbc:Endothelin_receptor_antagonists dbr:Pulmonary_hypertension dbr:Endothelin dbr:Endothelin_receptor_antagonist dbr:Bosentan dbr:Pfizer dbc:Benzodioxoles dbc:Chloroarenes dbr:Small_molecule dbr:Constipation dbc:Hepatotoxins dbr:Liver dbr:Sildenafil dbr:Clinical_trial dbr:Pulmonary_arterial_hypertension dbr:Warfarin dbr:Edema dbr:Food_and_Drug_Administration dbr:Nitric_oxide dbr:Flushing_(physiology) dbr:Nasal_congestion dbc:Thiophenes dbc:Withdrawn_drugs dbr:Headache dbc:Isoxazoles dbc:Sulfonamides dbr:Alanine_transaminase dbr:Kidney dbr:Hepatotoxicity dbr:Dizziness dbr:Aspartate_transaminase dbr:CYP2C9 dbr:CYP3A4 dbr:Insomnia dbr:Metabolism dbr:Upper_respiratory_tract_infection dbr:Adverse_effect_(medicine) dbr:Clotting dbr:Liver_enzyme dbr:4,5-(methylenedioxy)-''o''-tolyl]acetyl]-3-thiophenesulfonamide |
| dbp:atcPrefix |
2.0 |
| dbp:atcSuffix |
KX03 (en) |
| dbp:bioavailability |
70 (xsd:integer) |
| dbp:c |
18 (xsd:integer) |
| dbp:casNumber |
184036 (xsd:integer) |
| dbp:casSupplemental |
210421 (xsd:integer) |
| dbp:chembl |
282724 (xsd:integer) |
| dbp:chemspiderid |
21106381 (xsd:integer) |
| dbp:cl |
1 (xsd:integer) |
| dbp:drugbank |
DB06268 (en) |
| dbp:eliminationHalfLife |
36000.0 |
| dbp:excretion |
dbr:Kidney Fecal (en) |
| dbp:h |
15 (xsd:integer) |
| dbp:innEma |
sitaxentan sodium (en) |
| dbp:iupacName |
N--2-4,5-(methylenedioxy)-o-tolyl]acetyl]-3-thiophenesulfonamide (en) |
| dbp:iupharLigand |
3950 (xsd:integer) |
| dbp:kegg |
D07171 (en) |
| dbp:legalStatus |
Withdrawn (en) |
| dbp:licenceEu |
yes (en) |
| dbp:metabolism |
Hepatic (en) |
| dbp:n |
2 (xsd:integer) |
| dbp:o |
6 (xsd:integer) |
| dbp:proteinBound |
>99% (en) |
| dbp:pubchem |
216235 (xsd:integer) |
| dbp:routesOfAdministration |
Oral (en) |
| dbp:s |
2 (xsd:integer) |
| dbp:smiles |
Cc1cc2OCOc2cc1CCc3sccc3SNc4oncc4Cl (en) |
| dbp:synonyms |
TBC-11251 (en) |
| dbp:unii |
J9QH779MEM (en) |
| dbp:width |
225 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Drugbox dbt:Reflist dbt:Fdacite dbt:Antihypertensives_and_diuretics dbt:Drugs.com dbt:PAH_rx |
| dcterms:subject |
dbc:Endothelin_receptor_antagonists dbc:Benzodioxoles dbc:Chloroarenes dbc:Hepatotoxins dbc:Thiophenes dbc:Withdrawn_drugs dbc:Isoxazoles dbc:Sulfonamides |
| gold:hypernym |
dbr:Medication |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAntihypertensiveAgents yago:WikicatMolecularFormulas yago:WikicatOrphanDrugs yago:WikicatSulfonamides yago:Abstraction100002137 yago:Agent109190918 yago:Agent114778436 yago:Antibacterial102716205 yago:CausalAgent100007347 yago:Communication100033020 yago:Drug103247620 yago:Formula106816935 yago:Matter100020827 yago:Medicine103740161 yago:Message106598915 yago:MolecularFormula106817173 yago:PhysicalEntity100001930 dbo:Drug yago:Statement106722453 yago:Substance100020090 yago:SulfaDrug104352070 |
| rdfs:comment |
Sitaxentan (Handelsname: Thelin®, Hersteller: , eine Tochterfirma des Pfizer-Konzerns) ist ein Endothelin-Rezeptorantagonist und war als Alternative zu Ambrisentan und Bosentan als so genanntes Orphan-Arzneimittel zur Behandlung des seltenen Lungenbluthochdrucks (Pulmonale Hypertonie, NYHA-Stadium III) zugelassen. (de) Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity. (en) |
| rdfs:label |
Sitaxentan (de) Sitaxentan (en) |
| owl:sameAs |
freebase:Sitaxentan yago-res:Sitaxentan wikidata:Sitaxentan dbpedia-de:Sitaxentan dbpedia-sh:Sitaxentan dbpedia-sr:Sitaxentan https://global.dbpedia.org/id/53nwL |
| prov:wasDerivedFrom |
wikipedia-en:Sitaxentan?oldid=1073189152&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Sitaxentan.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Sitaxentan |
| is dbo:wikiPageRedirects of |
dbr:C18H15ClN2O6S2 dbr:ATC_code_C02KX03 dbr:ATCvet_code_QC02KX03 dbr:SitaxseNtan dbr:Sitaxsentan |
| is dbo:wikiPageWikiLink of |
dbr:Pulmonary_hypertension dbr:Endothelin dbr:Endothelin_receptor_antagonist dbr:Bosentan dbr:C18H15ClN2O6S2 dbr:ATC_code_C02KX03 dbr:ATCvet_code_QC02KX03 dbr:Sodium_salts dbr:Atrasentan dbr:ATC_code_C02 dbr:Thelin dbr:Icos dbr:List_of_signaling_peptide/protein_receptor_modulators dbr:List_of_withdrawn_drugs dbr:Signaling_peptide_receptor dbr:SitaxseNtan dbr:Sitaxsentan |
| is foaf:primaryTopic of |
wikipedia-en:Sitaxentan |
